Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation

Journal of Controlled Release

Volumn 203, Issue , 2015, Pages 16-22

  Rahimian, Sima ^a   Fransen, Marieke F ^b   Kleinovink, Jan Willem ^b   Christensen, Jonatan Riis ^a   Amidi, Maryam ^a   Hennink, Wim E ^a   Ossendorp, Ferry ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Freund's djuvant (IFA); Human papillomavirus (HPV); Incomplete; Nanoparticles; pLHMGA; Poly IC; Synthetic long peptide (SLP); Therapeutic cancer vaccine; TLR3 ligand

Indexed keywords

ANTIGENS; DISEASES; EMULSIFICATION; FUNCTIONAL POLYMERS; LIGANDS; MINERAL OILS; NANOPARTICLES; OIL SHALE; PEPTIDES; POLYMERS;

CANCER VACCINE; FREUND'S DJUVANT (IFA); HUMAN PAPILLOMAVIRUS; INCOMPLETE; PLHMGA; SYNTHETIC LONG PEPTIDE (SLP);

VACCINES;

CANCER VACCINE; FREUND ADJUVANT; MONTANIDE ISA 51; NANOPARTICLE; PEPTIDE VACCINE; POLY(DEXTRO,LEVO LACTIC CO HYDROXYMETHYL GLYCOLIC ACID); POLYESTER; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN E6; PROTEIN E7; SYNTHETIC LONG PEPTIDE; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; INTERFERON INDUCING AGENT; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; POLY(LACTIDE-CO-HYDROXYMETHYL GLYCOLIDE);

ANIMAL CELL; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; HYDROPHILICITY; IMMUNE RESPONSE; IN VITRO STUDY; INJECTION SITE; MOUSE; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; T LYMPHOCYTE ACTIVATION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; UTERINE CERVIX CANCER; ZETA POTENTIAL; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; PAPILLOMAVIRUS INFECTIONS; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VACCINATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CERVIX UTERI; FEMALE; FREUND'S ADJUVANT; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERFERON INDUCERS; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; POLY I-C; POLYESTERS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84922691981     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.02.006     Document Type: Article

References (62)

1. F. Bosch, A. Lorincz, N. Munoz, C. Meijer, and K. Shah The causal relation between human papillomavirus and cervical cancer J. Clin. Pathol. 55 2002 244 265
2. H. zur Hausen Papillomaviruses and cancer: from basic studies to clinical application Nat. Rev. Cancer 2 2002 342 350
3. J.M.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, K.V. Shah, P.J.F. Snijders, J. Peto, C.J.L.M. Meijer, and N. Munoz Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J. Pathol. 189 1999 12 19
4. N. Munoz, F. Bosch, X. Castellsague, M. Diaz, S. De Sanjose, D. Hammouda, K. Shah, and C. Meijer Against which human papillomavirus types shall we vaccinate and screen? The international perspective Int. J. Cancer 111 2004 278 285
5. N. Munoz, F.X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K.V. Shah, P.J.F. Snijders, and C.J.L.M. Meijer Epidemiologic classification of human papillomavirus types associated with cervical cancer N. Engl. J. Med. 348 2003 518 527
6. C.M. Wheeler Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing Nat. Clin. Pract. Oncol. 4 2007 224 235
7. A. Hildesheim, R. Herrero, S. Wacholder, A.C. Rodriguez, D. Solomon, M.C. Bratti, J.T. Schiller, P. Gonzalez, G. Dubin, C. Porras, S.E. Jimenez, and D.R. Lowy Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection - a randomized trial JAMA 298 2007 743 753
8. S. Tyring Human papillomavirus infections: epidemiology, pathogenesis, and host immune response J. Am. Acad. Dermatol. 43 2000 S18 S26
9. N.P. Tran, C. Hung, R. Roden, and T.C. Wu Control of HPV infection and related cancer through vaccination Recent Results Cancer Res. 193 2014 149 171
10. B. Ma, B. Maraj, Nam Phuong Tran, J. Knoff, A. Chen, R.D. Alvarez, C. Hung, and T. Wu Emerging human papillomavirus vaccines Expert Opin. Emerg. Drugs 17 2012 469 492
11. T. Liu, W.M. Hussein, I. Toth, and M. Skwarczynski Advances in peptide-based human papillomavirus therapeutic vaccines Curr. Top. Med. Chem. 12 2012 1581 1592
12. A. Bolhassani, E. Mohit, and S. Rafati Different spectra of therapeutic vaccine development against HPV infections Hum. Vaccin. 5 2009 671 689
13. M. Ressing, W. van Driel, R. Brandt, G. Kenter, J. de Jong, T. Bauknecht, G. Fleuren, P. Hoogerhout, R. Offringa, A. Sette, E. Celis, H. Grey, B. Trimbos, W. Kast, and C. Melief Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma J. Immunother. 23 2000 255 266
14. L. Muderspach, S. Wilczynski, L. Roman, L. Bade, J. Felix, L. Small, W. Kast, G. Fascio, V. Marty, and J. Weber A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive Clin. Cancer Res. 6 2000 3406 3416
15. R.E.M. Toes, R. Offringa, R.J.J. Blom, C.J.M. Melief, and W.M. Kast Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction Proc. Natl. Acad. Sci. U. S. A. 93 1996 7855 7860
16. S.H. van der Burg, M.S. Bijker, M.J.P. Welters, R. Offringa, and C.J.M. Melief Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy Adv. Drug Deliv. Rev. 58 2006 916 930
17. M.S. Bijker, C.J. Melief, R. Offringa, and S.H. van der Burg Design and development of synthetic peptide vaccines: past, present and future Expert Rev. Vaccines 6 2007 591 603
18. R.E.M. Toes, R.J.J. Blom, R. Offringa, W.M. Kast, and C.J.M. Melief Enhanced tumor outgrowth after peptide vaccination - functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors J. Immunol. 156 1996 3911 3918
19. M.S. Bijker, S.J.F. van den Eeden, K.L. Franken, C.J.M. Melief, R. Offringa, and S.H. van der Burg CD8(+) CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity J. Immunol. 179 2007 5033 5040
20. S. Zwaveling, S. Mota, J. Nouta, M. Johnson, G. Lipford, R. Offringa, S. van der Burg, and C. Melief Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides J. Immunol. 169 2002 350 358
21. R.A. Rosalia, E.D. Quakkelaar, A. Redeker, S. Khan, M. Camps, J.W. Drijfhout, A.L. Silva, W. Jiskoot, T. van Hall, P.A. van Veelen, G. Janssen, K. Franken, L.J. Cruz, A. Tromp, J. Oostendorp, S.H. van derBurg, F. Ossendorp, and C.J.M. Melief Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation Eur. J. Immunol. 43 2013 2554 2565
22. M.S. Bijker, S.J.E. van den Eeden, K.L. Franken, C.J.M. Melief, S.H. van der Burg, and R. Offringa Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation Eur. J. Immunol. 38 2008 1033 1042
23. C.J.M. Melief, and S.H. van der Burg Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines Nat. Rev. Cancer 8 2008 351 360
24. M.J.P. Welters, G.G. Kenter, S.J. Piersma, A.P.G. Vloon, M.J.G. Lowik, D.M.A. Berends-van der Meer, J.W. Drijfhout, A.R.P.M. Valentijn, A.R. Wafelman, J. Oostendorp, G.J. Fleuren, R. Offringa, C.J.M. Melief, and S.H. van der Burg Induction of tumor-specific CD4 + and CD8 + T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine Clin. Cancer Res. 14 2008 178 187
25. G.G. Kenter, M. Welters, M. Lowik, J. Drijfhout, R. Valentijn, J. Ostendorp, F. Gertjan, S. Van de Burg, and C. Melief Therapeutic HPV 16 vaccination with long E6 and E7 peptides shows immunological and clinical efficacy Gynecol. Oncol. 108 2008 S19-S19
26. G.G. Kenter, M.J.P. Welters, A.R.P.M. Valentijn, M.J.G. Lowik, D.M.A. Berends-van der Meer, A.P.G. Vloon, F. Essahsah, L.M. Fathers, R. Offringa, J.W. Drijfhout, A.R. Wafelman, J. Oostendorp, G.J. Fleuren, S.H. van der Burg, and C.J.M. Melief Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N. Engl. J. Med. 361 2009 1838 1847
27. J. Aucouturier, L. Dupuis, S. Deville, S. Ascarateil, and V. Ganne Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines Expert Rev. Vaccines 1 2002 111 118
28. J. Aucouturier, S. Ascarateil, and L. Dupuis The use of oil adjuvants in therapeutic vaccines Vaccine 24 Suppl. 2 2006 S2-44-5
29. J.M. Silva, M. Videira, R. Gaspar, V. Preat, and H.F. Florindo Immune system targeting by biodegradable nanoparticles for cancer vaccines J. Control. Release 168 2013 179 199
30. D.E. Speiser, D. Lienard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A.M. Krieg, J.C. Cerottini, and P. Romero Rapid and strong human CD8 + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909 J. Clin. Invest. 115 2005 739 746
31. A. Shibaki, and S. Katz Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant Exp. Dermatol. 11 2002 126 134
32. S. Akira, K. Takeda, and T. Kaisho Toll-like receptors: critical proteins linking innate and acquired immunity Nat. Immunol. 2 2001 675 680
33. C. Melief, S. van der Burg, R. Toes, F. Ossendorp, and R. Offringa Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes Immunol. Rev. 188 2002 177 182
34. B. Salaun, S. Lebecque, S. Matikainen, D. Rimoldi, and P. Romero Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin. Cancer Res. 13 2007 4565 4574
35. F. Steinhagen, T. Kinjo, C. Bode, and D.M. Klinman TLR-based immune adjuvants Vaccine 29 2011 3341 3355
36. A.M. Hafner, B. Corthesy, and H.P. Merkle Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant Adv. Drug Deliv. Rev. 64 2013 1386 1399
37. E. Schlosser, M. Mueller, S. Fischer, S. Basta, D.H. Busch, B. Gander, and M. Groettrup TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses Vaccine 26 2008 1626 1637
38. S. Hamdy, O. Molavi, Z. Ma, A. Haddadi, A. Alshamsan, Z. Gobti, S. Elhasi, J. Samuel, and A. Lavasanifar Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8(+) T cell-mediated anti-tumor immunity Vaccine 26 2008 5046 5057
39. C. Wischke, J. Zimmermann, B. Wessinger, A. Schendler, H. Borchert, J.H. Peters, T. Nesselhut, and D.R. Lorenzen Poly(I:C) coated PLGA microparticles induce dendritic cell maturation Int. J. Pharm. 365 2009 61 68
40. S. De Koker, B.N. Lambrecht, M.A. Willart, Y. van Kooyk, J. Grooten, C. Vervaet, J.P. Remon, and B.G. De Geest Designing polymeric particles for antigen delivery Chem. Soc. Rev. 40 2011 320 339
41. H. Toledo, A. Baly, O. Castro, S. Resik, J. Laferte, F. Rolo, L. Navea, L. Lobaina, O. Cruz, J. Miguez, T. Serrano, B. Sierra, L. Perez, M.E. Ricardo, M. Dubed, A.L. Lubian, M. Blanco, J.C. Millan, A. Ortega, E. Iglesias, E. Penton, Z. Martin, J. Perez, M. Diaz, and C.A. Duarte A phase I clinical trial of a mufti-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers Vaccine 19 2001 4328 4336
42. R. Gupta, E. Relyveld, E. Lindblad, B. Bizzini, S. Benefraim, and C. Gupta Adjuvants - a balance between toxicity and adjuvanticity Vaccine 11 1993 293 306
43. M. Leemhuis, C. van Nostrum, J. Kruijtzer, Z. Zhong, M. ten Breteler, P. Dijkstra, J. Feijen, and W. Hennink Functionalized poly(alpha-hydroxy acid)s via ring-opening polymerization: toward hydrophilic polyesters with pendant hydroxyl groups Macromolecules 39 2006 3500 3508
44. M. Leemhuis, J.A.W. Kruijtzer, C.F. van Nostrurn, and W.E. Hennink In vitro hydrolytic degradation of hydroxyl-functionalized poly(alpha-hydroxy acid)s Biomacromolecules 8 2007 2943 2949
45. A.H. Ghassemi, M.J. van Steenbergen, A. Barendregt, H. Talsma, R.J. Kok, C.F. van Nostrum, D.J.A. Crommelin, and W.E. Hennink Controlled release of octreotide and assessment of peptide acylation from poly(D, l-lactide-co-hydroxymethyl glycolide) compared to plga microspheres Pharm. Res. 29 2012 110 120
46. Y. Liu, A.H. Ghassemi, W.E. Hennink, and S.P. Schwendeman The microclimate pH in poly(D, l-lactide-co-hydroxymethyl glycolide) microspheres during biodegradation Biomaterials 33 2012 7584 7593
47. S. Rahimian, J.W. Kleinovink, M.F. Fransen, L. Mezzanotte, H. Gold, P. Wisse, H. Overkleeft, M. Amidi, W. Jiskoot, C.W. Löwik, F. Ossendorp, and W.E. Hennink Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: in vivo tracking and evaluation of antigen-specific CD8 + T cell immune response Biomaterials 37 2015 469 477
48. F. Kazazi-Hyseni, J. Zandstra, E. Popa, R. Goldschmeding, A. Lathuile, G. Veldhuis, C. Van Nostrum, W. Hennink, and R. Kok Biocompatibility of poly(d, l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcutaneous and subcapsular renal injection Int. J. Pharm. 2015 10.1016/j.ijpharm.2014.12.014 (in press)
49. A.L. Silva, R.A. Rosalia, A. Sazak, M.G. Carstens, F. Ossendorp, J. Oostendorp, and W. Jiskoot Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation Eur. J. Pharm. Biopharm. 83 2013 338 345
50. Y. Krishnamachari PLGA Microparticle Based Vaccine Carriers for an Improved and Efficacious Tumor Therapy PhD thesis 2011 University of Iowa (http://ir.uiowa.edu/etd/2922)
51. K. Lin, F. Guarnieri, K. StaveleyOCarroll, H. Levitsky, J. August, D. Pardoll, and T. Wu Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen Cancer Res. 56 1996 21 26
52. S. van Duikeren, M.F. Fransen, A. Redeker, B. Wieles, G. Platenburg, W. Krebber, F. Ossendorp, C.J.M. Melief, and R. Arens Vaccine-induced effector-memory cd8(+) t cell responses predict therapeutic efficacy against tumors J. Immunol. 189 2012 3397 3403
53. J. Altman, P. Moss, P. Goulder, D. Barouch, M. McHeyzerWilliams, J. Bell, A. McMichael, and M. Davis Phenotypic analysis of antigen-specific T lymphocytes Science 274 1996 94 96
54. R.C. Mundargi, V.R. Babu, V. Rangaswamy, P. Patel, and T.M. Aminabhavi Nano/micro technologies for delivering macromolecular therapeutics using poly(D, l-lactide-co-glycolide) and its derivatives J. Control. Release 125 2008 193 209
55. P. Couvreur, and F. Puisieux Nanoparticles and microparticles for the delivery of polypeptides and proteins Adv. Drug Deliv. Rev. 10 1993 141 162
56. W. Ma, M. Chen, S. Kaushal, M. McElroy, Y. Zhang, C. Ozkan, M. Bouvet, C. Kruse, D. Grotjahn, T. Ichim, and B. Minev PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses Int. J. Nanomedicine 7 2012 1475 1487
57. Z. Zhang, S. Tongchusak, Y. Mizukami, Y.J. Kang, T. Ioji, M. Touma, B. Reinhold, D.B. Keskin, E.L. Reinherz, and T. Sasada Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery Biomaterials 32 2011 3666 3678
58. A.M. Tinsley-Bown, R. Fretwell, A.B. Dowsett, S.L. Davis, and G.H. Farrar Formulation of poly(d, l-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery J. Control. Release 66 2000 229 241
59. V. Filipe, A. Hawe, and W. Jiskoot Critical evaluation of nanoparticle tracking analysis (nta) by nanosight for the measurement of nanoparticles and protein aggregates Pharm. Res. 27 2010 796 810
60. D.A. Wick, and J.R. Webb A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors Vaccine 29 2011 7857 7866
61. S. Chen, R. Ou, J. Tang, X. Deng, Y. Wu, J.C. van Velkinburgh, B. Ni, and Y. Xu Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150 Cancer Epidemiol. 37 2013 172 178
62. Z.R. Cui, and F. Qiu Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model Cancer Immunol. Immunother. 55 2006 1267 1279